KFDA Takes Detailed Safety Review on Celebrex

Published: 2004-12-24 06:56:00

Updated: 2004-12-24 06:56:00

The Korea Food and Drug Administration (KFDA) announced that it is taking a detailed safety review on Pfizer’s Celebrex, reflecting the U.S. Food and Drug Administration (FDA)’s recent citation on the safety issues of Celebrex from the study conducted by the U.S. National Cancer Institute (NCI).
...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK